Eli Lilly’s stock closed at $771.75, slipping 3.45% and lagging the broader market. The company’s shares fell despite outperforming the medical sector over the past month. Analysts eagerly await its ...

In the most recent trading session, Eli Lilly (LLY) closed at $771.75, indicating a -3.45% shift from the previous trading day.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

Eli Lilly (NYSE:LLY) drew attention on Friday after JPMorgan reiterated its bullish stance on the stock, raising its price ...

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Eli Lilly’s stock closed at $786.92, marking a 1.19% gain, outpacing the broader market. Despite a 3.66% drop in the past ...